An-Nahar: A new personalized mRNA vaccine lowers the risk of melanoma recurrence by 42% after surgery when used with the immunotherapy “Keytruda,” according to the results of a study involving more than…
Machine translation of an attributed source excerpt. Consult the original report to verify details. Translated from original reporting in another language.
Ad-Diyar: Results of an advanced clinical trial showed that an experimental personalized vaccine based on messenger RNA (mRNA) technology, developed by Merck and Moderna, helped reduce the risk of skin cancer recurrence or death by 42% when used with the immunotherapy Keytruda. The vaccine is known as…
MTV Lebanon: Lebanese trucks stranded at the border after the closure of the Nassib crossing have re-entered…
Ad-Diyar: Lamine Yamal, the Barcelona star, stole the spotlight at the 2026 Ballon d’Or ceremony, held in the British capital, London, after appearing in a black suit adorned with a large pink piece on the lapel, in…
/file/attachments/2409/cancer-immunotherapy-e8a50f02_764883.png)
/file/attachments/2411/Untitled_835369.jpg)